Treatment

A clinical trial involving 500 patients has shown that the daily oral drug daraxonrasib may significantly extend survival in advanced pancreatic cancer, an outcome researchers are describing as a major breakthrough. In the study presented at the American Society of Clinical Oncology annual meeting, patients receiving daraxonrasib lived a median of 13.2 months, compared with […]

The phase 3 BREAKWATER trial  shows that a targeted combination of encorafenib (Braftovi), cetuximab (Erbitux), and FOLFIRI chemotherapy significantly improves outcomes for patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer. The regimen is now considered a new standard of care following FDA traditional approval in February 2026. The study enrolled 147 patients and compared

Abemaciclib (Verzenio) has shown the first positive phase 3 trial result in advanced or metastatic dedifferentiated liposarcoma (DDLS), according to the SARC041 study. The oral CDK4/6 inhibitor significantly delayed disease progression compared with placebo in a cancer type with very limited treatment options. The trial enrolled 108 patients with progressive, recurrent, or metastatic DDLS randomized

The phase 3 frontMIND trial has demonstrated that adding tafasitamab (Monjuvi) and lenalidomide (Revlimid) to standard R-CHOP chemotherapy improves outcomes for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL). After a median follow-up of 35.2 months, the combination reduced the risk of disease progression or death by 25% compared with R-CHOP alone. Two-year

Daraxonrasib (RMC-6236) delivered breakthrough results in the phase 3 RASolute 302 trial offering a major advance for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The study enrolled 500 patients whose cancer had progressed after one prior chemotherapy regimen and compared oral daraxonrasib with standard chemotherapy options. Patients treated with daraxonrasib achieved a median overall

A phase 3 trial showed that the TMC-I regimen significantly improved survival in patients with platinum-sensitive, advanced head and neck squamous cell carcinoma receiving first-line palliative treatment. Conducted at the Tata Memorial Centre in India, the study compared TMC-I—an oral combination of methotrexate, erlotinib, and celecoxib plus ultra-low-dose nivolumab—with standard paclitaxel-carboplatin chemotherapy in 422 patients.

The phase 3 RAMPART trial found that adjuvant immunotherapy with durvalumab plus tremelimumab significantly reduced the risk of recurrence in patients with high-risk renal cell carcinoma following surgery. After a median follow-up of 3.5 years, the combination achieved a 3-year disease-free survival (DFS) rate of 80%, compared with 72% for active monitoring, translating to a

New subgroup data from the phase 3 ROSELLA trial show that adding relacorilant (Lifyorli) to nab-paclitaxel significantly improves survival for patients with platinum-resistant ovarian cancer, regardless of prior taxane treatment history. With a median follow-up of 24.8 months, patients receiving the combination therapy achieved a median overall survival of 16.0 months, compared with 11.9 months

Updated results from the RUBY phase 3 trial suggest that adding the immunotherapy drug dostarlimab to standard chemotherapy may offer the potential for long-term cure in patients with advanced or recurrent dMMR/MSI-H endometrial cancer. After a median follow-up of 55.6 months, patients receiving dostarlimab plus carboplatin and paclitaxel achieved a 4-year progression-free survival rate of

B7-H3 is emerging as one of the most promising targets in cancer therapy because it is highly expressed across many solid tumors while remaining limited in normal tissues. Several antibody-drug conjugates (ADCs) targeting B7-H3 are now showing encouraging early results in lung, prostate, and gynecologic cancers. In small cell lung cancer, Ifinatamab deruxtecan received FDA